Fintel reports that on December 9, 2024, Jefferies upgraded their outlook for Kodiak Sciences (NasdaqGM:KOD) from Hold to Buy.
Analyst Price Forecast Suggests 45.29% Downside
As of December 3, 2024, the average one-year price target for Kodiak Sciences is $4.28/share. The forecasts range from a low of $2.02 to a high of $6.30. The average price target represents a decrease of 45.29% from its latest reported closing price of $7.83 / share.
See our leaderboard of companies with the largest price target upside.
The projected annual revenue for Kodiak Sciences is 27MM. The projected annual non-GAAP EPS is -4.11.
What is the Fund Sentiment?
There are 241 funds or institutions reporting positions in Kodiak Sciences. This is an decrease of 17 owner(s) or 6.59% in the last quarter. Average portfolio weight of all funds dedicated to KOD is 0.02%, an increase of 1.07%. Total shares owned by institutions increased in the last three months by 1.38% to 42,678K shares. 
The put/call ratio of KOD is 0.21, indicating a bullish outlook.
What are Other Shareholders Doing?
Baker Bros. Advisors holds 17,310K shares representing 32.97% ownership of the company. No change in the last quarter.
Acadian Asset Management holds 1,954K shares representing 3.72% ownership of the company. In its prior filing, the firm reported owning 1,965K shares , representing a decrease of 0.58%. The firm increased its portfolio allocation in KOD by 11.39% over the last quarter.
ICONIQ Capital holds 1,017K shares representing 1.94% ownership of the company. No change in the last quarter.
TCG Crossover Management holds 1,008K shares representing 1.92% ownership of the company. In its prior filing, the firm reported owning 900K shares , representing an increase of 10.73%. The firm increased its portfolio allocation in KOD by 1.14% over the last quarter.
VTSMX - Vanguard Total Stock Market Index Fund Investor Shares holds 982K shares representing 1.87% ownership of the company. No change in the last quarter.
Kodiak Sciences Background Information
(This description is provided by the company.)
Kodiak Sciences Inc. is a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics to treat high prevalence retinal diseases. Founded in 2009, Kodiak is focused on bringing new science to the design and manufacture of next generation retinal medicines to prevent and treat the leading causes of blindness globally. Its ABC Platform™ uses molecular engineering to merge the fields of antibody-based and chemistry-based therapies and is at the core of Kodiak's discovery engine. Kodiak's lead product candidate, KSI-301, is a novel anti-VEGF antibody biopolymer conjugate being developed for the treatment of retinal vascular diseases including age-related macular degeneration, the leading cause of blindness in elderly patients in the developed world, and diabetic eye diseases, the leading cause of blindness in working-age patients in the developed world. Kodiak has leveraged its ABC Platform to build a pipeline of product candidates in various stages of development including KSI-501, its bispecific anti-IL-6/VEGF biopolymer conjugate for the treatment of neovascular retinal diseases with an inflammatory component, and the company is expanding its early research pipeline to include ABC Platform based triplet inhibitors for multifactorial retinal diseases such as dry AMD and glaucoma. Kodiak is based in Palo Alto, CA.
Fintel is one of the most comprehensive investing research platforms available to individual investors, traders, financial advisors, and small hedge funds.
Our data covers the world, and includes fundamentals, analyst reports, ownership data and fund sentiment, options sentiment, insider trading, options flow, unusual options trades, and much more. Additionally, our exclusive stock picks are powered by advanced, backtested quantitative models for improved profits.
This story originally appeared on Fintel.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
